doi: 10.1016/j.biochi.2022.05.005.
Epub 2022 May 13.
Melatonin as an adjuvant treatment modality with doxorubicin [Biochimie 200 (2022) 1-7]
Affiliations
- PMID: 35569703
- DOI: 10.1016/j.biochi.2022.05.005
Item in Clipboard
Melatonin as an adjuvant treatment modality with doxorubicin [Biochimie 200 (2022) 1-7]
Biochimie.
2022 Sep.
Retraction in
- 10.1016/j.biochi.2022.05.005
No abstract available
Similar articles
-
Melatonin as an adjuvant treatment modality with doxorubicin.Biochimie. 2022 Nov;202:49-55. doi: 10.1016/j.biochi.2022.06.007. Epub 2022 Jun 22. Biochimie. 2022. PMID: 35752222
-
Anti-drug resistance, anti-inflammation, and anti-proliferation activities mediated by melatonin in doxorubicin-resistant hepatocellular carcinoma: in vitro investigations.Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun;396(6):1117-1128. doi: 10.1007/s00210-023-02385-w. Epub 2023 Jan 18. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36651944 Free PMC article.
-
Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin.J Pineal Res. 2013 Sep;55(2):184-94. doi: 10.1111/jpi.12061. Epub 2013 May 25. J Pineal Res. 2013. PMID: 23711089
-
Melatonin in cancer management: progress and promise.Cancer Res. 2006 Oct 15;66(20):9789-93. doi: 10.1158/0008-5472.CAN-06-1776. Cancer Res. 2006. PMID: 17047036 Review.
-
Molecular and Biological Functions of Melatonin in Endometrial Cancer.Curr Drug Targets. 2020;21(5):519-526. doi: 10.2174/1389450120666190927123746. Curr Drug Targets. 2020. PMID: 31560286 Review.
Cited by
-
Potential of melatonin to reverse epigenetic aberrations in oral cancer: new findings.EXCLI J. 2023 Dec 12;22:1280-1310. doi: 10.17179/excli2023-6624. eCollection 2023. EXCLI J. 2023. PMID: 38234969 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
